biostudies-literatureAllemani CCancer Research UKChildren with Cancer UKNCI NIH HHSIntramural CDC HHS1023-1075https://www.ebi.ac.uk/biostudies/studies/S-EPMC5879496biostudies-literatureUnknown391(10125)<h4>Background</h4>In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014.<h4>Methods</h4>CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights.<h4>Findings</h4>For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 33·4%, and 24·8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark).<h4>Interpretation</h4>The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer.<h4>Funding</h4>American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation.Lancet (London, England)Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.PMC5879496CC999999P01 CA02884217-24616148Saint-Jacques NThursfield VZorzi MMatsuda TChiolero AIwasa KNishri DEDickman PSanchez Perez MJDe Souza PCFKarasahin FEZhaolai HNakagawa HCavalieri d'Oro LMaksimowicz KMGuizard AVPreux PMMatz MRiddle BFanetti ACTurkkoylu AKeitheri Cheteri MBBushhouse SBianconi FHerrera VMSchwartz SMOlafsdottir EJSiesling STumino RHerrmann CMcClure CALi YHRamirez MYordanova MRde Oliveira JCBeran TWon YJRoshandel GJanes TAMoreno FBayakly RForjaz de Lacerda GCarballo Quintero BDaoprasert KJoachim CTurner DCornet EJunhua QCaldarella AWhite CTucker TCStorm HRees JRCastillo JWei KCowppli-Bony AHuws DWMang WKFerretti SZhang JHCelesia MVBarrios ESato SMarrer EZhu JNaito MOrlov AESato MHolt AClough-Gorr KReca ENgan KCLaunoy GWiggins CMolina ECaiazzo ALBayo SYepez Chamorro MCLu YQAdam FMonnereau ARicci PBlaszczyk JBarchielli AZwierko MRao CMounier MCoviello EDong JSantos MODrosik KPoquioma EYoshii MRuppert LPCalleja NMelcarne ADe Angelis RStaehelin KEspinoza REHolleczek BMagi MGarcia LCirilli CEngholm GMacni JNakata KCoureau GCoza DFarrugia HZavala DBoschetti LJayalekshmi PALiu LNakata IRashbass JStabenow RSassatelli RVeneziano CLABradshaw DCastaing MSant MDeloumeaux JDowling JGavin AHerrmann DAJurado DMPikalova LVClark DIHe YTMiller-Gianturco PLi YYJohnson FZhao DLLevin GMRoberts-Johnson JGatti LLapotre-Ledoux BYakut CIWalton RSweeney CZaidi ZDyzmann-Sroka AVicentini MNemoto YEspinola SBAparicio Aravena MDaoulas MContiero PVelten MLavecchia AMHalat YArias-Ortiz NECueva PKozie SZborovskaya AAOgunbiyi OJAlonso RMcCrate FRVittadello FArveux PBerrino FCONCORD Working GroupKepska KGordon PSgargi PZanetti RRousseau DLPiffer SKieschke JWoods RRLohden IRubertone JJRebelo MSPawlish KSQuarta FKnowlton RCQuinto RRivera Gomez RShibata ASanjaajmats EMorantes DYepez JGWoronoff ASMariotto AAmadeo BMarcos-Gragera RWiangnon SHackl MKoscianska BPlouvier SAdamcik JNarisawa RSchaffar RCavallo RSzewczyk SSriplung HMigliore Santiago PArdizzone ABlankenship SETroussard XYoshida KSanhueza Monsalve JSundseth HGrosclaude PAitken JStiller CABrockhouse JTJegu JWohler BTagliabue GJohnson CJMiyagi KYou HHuang SQKeinan-Boker LGentilini MAAzevedo E Silva GCandela GEgorova AGMendoza MColonna MBulliard JLRedondas RMerletti FEsteve JNikiforuk CRadziszewska AUMaspero SMolinie FAb Manan ADeapen DKanemura SGoujon SNarimatsu HSangrajrang STurhan DAntunes LRharbaoui FRognoni MGalan Alvarez YHBeggiato SPhillips CEFalcini FBara SStuart-Panko HDelafosse PWilsdorf-Kohler HEspinoza JRFu FXVenn AKaizaki YNennecke ALWalsh PMJohnson ATTrojanowski MBorciani EFiliberti RAKatalinic ALatorre MRDOWeir HKDidkowska JAChen JSRamos Montserrat MCress RDi Carlo VCesaraccio RGos ATisano FArdanaz EEChen JGChirlaque MDD'Argenzio ABonaventure ALemons DBray FDeas AJManraj SSWilliams MAKuehni CEGrosso GDel Pino KGradalska-Lampart MSong GHMiyashiro ISekerija MFusco MRusso AGTeramoto NCarone SKataki ACTudev UDelgado STretarre BGiacomin AKamsa-Ard SKhan FChalker EAlverson GMei DGuevara MMSomdyala NIMKhan SRego RAUtada MSangkitipaiboon SZvolsky MGeorge JTSchymura MJSakaguchi MNimri OBastos JCarrillo RGola GMierzwa TPurwin-Porowska EBouzbid SEberle ACurado MPBravo LEO'Brien DKOrazio SEckstrand AMu HJMalila NWu THRycroft RRachet BBroggio JCalabrano GHZimmerman HJAlmon LZeng HSeghini PHamdi-Cherif MWojcik-Tomaszewska JTukiendorf AAlberich CAl Khater AMSeppa KHendrix JLuttmann SAllemani CStroup ALigier KBendahhou KIbanez SGGeater SLRachtan JTurculet ADFreeman TVisser OKwong SOki IPetridou ECapocaccia RLaronningen SChiang CJFan MMichiara MMaynadie MNandakumar AHurley DMVicente-Raneda MMazzucco WPhung HSchwartz AGLei YFitzpatrick DUsala MFrick HNoonan GMaspoli-Conconi MLeklob ACuccaro FHenau KGurbuz TSugiyama HBolick SWPineros MAleinikova OVVilardell Gil MLAvelina IBouvier AMStokes BCGozdz SUribe CJAgius DVjushkov DMMcKinley MKog ILacour BStracci FAlawadhi ECromartie BBuasom RLaranja Pontes JHerget KCarulla MLiu SZTarocinska KBorchers REl Mistiri MMGershman STJaramillo LGiorgetti SBouvier VRugge MLi WLaporte CVan Eycken LMaule MMHarewood RLewis CMazzoleni GMorris CRyan STryggvadottir LMolong LFarley SMagoni MTanaka LFGanry OMontel LTortolero-Luna GCopeland GEPettersson DRohrmann SAird KGLarranaga NUcuncu NJung KWNavarro CCassetti TTalerczyk MBouchardy CGusenkova LZucchetto ASafaei Diba CCavusoglu YMaurina AVigneau FSilverman BGAltinisik MLee WCCeylan OBrustolin AKey CCarrozzi GGatta GEmrich KMiranda AEdwards BKRegagba DMartinez-Reyes FOno CWilson RGuthridge SPeris-Bonet RMalekzadeh RSebastian PValerianova ZUhry ZMezyk RVriends KALaspada WDJin FSchwenn MZhu FDSirri EScuderi TZhang BLi QLMangone LZadnik VFabowale ABossard NEser SColeman MPGiljahn LKKahn ARCusimano RWyborska MShalkow Klincovstein JDiumenjo MCLazarevich OChen WQMueller LRedmond SMKudyakov LALim GHVincerzevskiene IBlaga LMLynch CFDirican OBuzzoni CMatthes KLHood MSlack SJSampietro GTorres PJackson-Thompson JMacIntyre MGomez SLGu XPGalceran JSilva MABielska-Lasota MBiao WWhiteside MALima CAPildava SDemetriou AVSerraino DWard KCVargas SDusek LNishimura MMayer-da-Silva AZhou YZhou XGe HMVitale MFYi HGarcia LSCurrow DMoki FWojciechowska UKurosawa KYang YLEisemann NPouchieu CKumar VGuo GPGalaz JCFernandez-Delgado RTobori FKumcher IBrown HHerrera AAElbasmi APongnikorn DKrishnatreya MGalasso RWang JCheick Bougadari TPirino DRWang NOrtelli LIto HLipunova NValkov MTeo YYHuang BSutera Sardo ARadhakrishnan SLopez de Munain ARobaszkiewicz MRogers DBMoller BWu XCFita RSlocumb RMMalicki RGrandpre JPannozzo FStephens RD'Onise KFukushima NInnos KKose TVeneziano DBClavel JAktas UBordoni AZeissig SRAsquez RAJiang CXMancuso PKonzelmann IFranch Sureda PBaldi IPriest KGreen MDContrino MLOchir CBhakkan BPrimic-Zakelj MPrudnikova ONiksic MMincuzzi AMeguenni KKumar ECamey BRosso SHsieh MCHattori MfalseGlobal surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.<h4>Background</h4>In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014.<h4>Methods</h4>CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights.<h4>Findings</h4>For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 33·4%, and 24·8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark).<h4>Interpretation</h4>The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer.<h4>Funding</h4>American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation.2018-01-01T00:00:00Z2018 Mar2024-11-13T09:01:37.014Z2019-08-04T07:03:14ZS-EPMC58794962939526910.1016/S0140-6736(17)33326-310.1016/s0140-6736(17)33326-3